Marie DeVito Leads Progenitor Cell Therapy’s Quality Assurance and Quality Control Program

Progenitor Cell Therapy, LLC (PCT), a leading full service cell therapy development and contract manufacturing company, is pleased to announce Marie DeVito as Senior Director of Quality Assurance and Quality Control.

HACKENSACK, New Jersey (PRWEB) April 19, 2006 -- Progenitor Cell Therapy, LLC (PCT), a leading full service cell therapy development and contract manufacturing company, is pleased to announce Marie DeVito as Senior Director of Quality Assurance and Quality Control.

“Marie’s proven track record and expertise in developing, streamlining and implementing quality assurance systems and procedures significantly strengthens our team,” states Robert A. Preti PhD., President and Chief Scientific Officer of PCT.

Marie is a quality assurance executive with over 20 years of experience in corporate and contract manufacturing environments. Over the course of her career, Marie has served as the FDA liaison for numerous projects and has developed significant expertise in quality systems and procedures; quality agreements and metrics; GMP investigations; GMP internal and supplier auditing; CMC QA review and approval; technology transfer and validation; and electronic document systems and change control.

Prior to joining PCT, Marie was Director of Research Quality Assurance (RQA) - Quality Systems at Purdue Pharma L.P. in Ardsley, New York, where she was responsible for managing documentation control and clinical supplies approval and release.

“Marie’s exceptional leadership skills will be integral to our mandate of continually developing systems that serve both the current and future needs of our clients,” states Andrew L. Pecora, MD, FACP, PCT’s Chairman and Chief Executive Officer.

Marie received a Masters of Science in Biology with a concentration in Microbiology from Fairleigh Dickinson University.

About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies by providing cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality systems strategies. PCT’s cG(x)P nationwide network enables it to provide a full spectrum of support including preclinical development, clinical research, collection, processing, tissue storage, diagnostics/biologic product testing, manufacturing, distribution and transportation. For more information, please visit www.progenitorcelltherapy.com.

Contact:
George Goldberger
Chief Business Officer
Progenitor Cell Therapy, LLC
(201) 883-5314

###